Skip to content

Quick ratio at other companies

Celcuity logo
CelcuityCELC
12.3×+5.7×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
6.8×-6.7×
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
21×+15.9×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
10.7×-3.2×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
15.1×+10.0×

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.8B+300%

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×
Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s quick ratio?
Relay Therapeutics, Inc. (RLAY) reported quick ratio of 22.1× in Q1 2026.
How has Relay Therapeutics, Inc.'s quick ratio changed year-over-year?
Relay Therapeutics, Inc.'s quick ratio increased by 10.9% year-over-year, from 20× to 22.1×.
What is the long-term trend for Relay Therapeutics, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s quick ratio has grown at a -16.7% compound annual growth rate (CAGR), from 56.5× to 22.6×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.